Marixino (Memantine)
NMDA receptor antagonist for moderate to severe Alzheimer's disease
Quick Facts: Marixino
Key Takeaways
- Marixino (memantine) is prescribed for moderate to severe Alzheimer's disease and works by blocking excessive glutamate activity in the brain.
- The dose must be gradually increased over 4 weeks, starting at 5 mg daily and reaching a maintenance dose of 20 mg daily.
- Common side effects include headache, dizziness, drowsiness, and constipation – most are mild and transient.
- Dose adjustment is required for patients with moderate to severe kidney impairment (maximum 10 mg daily).
- Marixino can be safely combined with cholinesterase inhibitors such as donepezil, as recommended by NICE guidelines.
What Is Marixino and What Is It Used For?
Quick Answer: Marixino is a brand name for memantine hydrochloride, an NMDA receptor antagonist used to treat the symptoms of moderate to severe Alzheimer's disease. It does not cure the disease but may help slow the decline in thinking, memory, and the ability to perform everyday activities.
Marixino belongs to a group of medicines known as anti-dementia drugs. Its active substance, memantine hydrochloride, works by targeting a specific type of receptor in the brain called the NMDA (N-methyl-D-aspartate) receptor. In Alzheimer's disease, abnormally high levels of a chemical messenger called glutamate build up in the brain. This excessive glutamate overstimulates NMDA receptors, leading to a constant “background noise” that damages nerve cells and interferes with the brain's ability to form new memories and learn.
Memantine is classified as a moderate-affinity, uncompetitive, voltage-dependent NMDA receptor antagonist. This means it selectively blocks the harmful effects of chronically elevated glutamate levels while still allowing the normal bursts of glutamate activity required for learning and memory formation. This unique mechanism of action distinguishes memantine from the cholinesterase inhibitors (such as donepezil, rivastigmine, and galantamine) that are typically used in mild to moderate Alzheimer's disease.
Clinical trials have demonstrated that memantine provides statistically significant, though modest, benefits in cognition, global function, activities of daily living, and behaviour in patients with moderate to severe Alzheimer's disease. A Cochrane systematic review (McShane et al.) confirmed that memantine has a small but clinically detectable effect across multiple outcome domains. The European Medicines Agency (EMA) and the National Institute for Health and Care Excellence (NICE) in the United Kingdom both recommend memantine as a treatment option for moderate to severe Alzheimer's disease.
Marixino is manufactured by KRKA and is available as film-coated tablets containing 10 mg of memantine hydrochloride. It is classified under the Anatomical Therapeutic Chemical (ATC) code N06DX01, within the group of “other anti-dementia drugs.” Marixino is a prescription-only medicine and should only be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia.
What Should You Know Before Taking Marixino?
Quick Answer: Before starting Marixino, tell your doctor about any kidney problems, history of seizures, heart conditions, or if you are taking other NMDA-active medicines. Marixino is not recommended during pregnancy or breastfeeding.
Contraindications
You should not take Marixino if you are allergic (hypersensitive) to memantine hydrochloride or any of the other ingredients in the tablet. Signs of an allergic reaction include rash, itching, swelling of the face or throat, and difficulty breathing. If you have ever experienced a severe allergic reaction to any memantine-containing product, you must not take Marixino.
Warnings and Precautions
Talk to your doctor or pharmacist before taking Marixino if you have any of the following conditions, as special care, dose adjustments, or additional monitoring may be needed:
- Epilepsy or a history of seizures: Memantine may theoretically lower the seizure threshold. Although seizures are rare, patients with a history of convulsions should be closely monitored during treatment.
- Recent heart attack (myocardial infarction): Limited data are available on the safety of memantine in patients who have recently had a heart attack. Your doctor will weigh the benefits against the risks.
- Heart failure: Patients with uncompensated congestive heart failure (NYHA class III–IV) were not included in clinical trials. Use with caution in this group.
- High blood pressure: Memantine can occasionally raise blood pressure. Patients with uncontrolled hypertension should have their blood pressure monitored regularly.
- Kidney impairment: Memantine is primarily eliminated by the kidneys. A dose reduction is required in patients with moderate to severe renal impairment (see Dosage section).
- Conditions that raise urine pH: Alkaline urine (caused by renal tubular acidosis, severe urinary tract infection with Proteus bacteria, or a strict vegetarian diet) can significantly reduce the kidneys' ability to excrete memantine, potentially leading to increased drug levels in the blood.
Pregnancy and Breastfeeding
Marixino should not be used during pregnancy unless your doctor considers it clearly necessary. There are no clinical studies on the use of memantine in pregnant women. Animal studies have shown that memantine may reduce foetal growth at exposure levels similar to or slightly higher than those used in humans. The actual risk to the human foetus is unknown.
It is not known whether memantine passes into breast milk. However, given the lipophilic nature of the substance, excretion into breast milk is considered likely. Women taking Marixino should not breastfeed. If breastfeeding is essential, the treatment with memantine should be discontinued after discussion with your doctor.
There are no human data on the effects of memantine on fertility. Animal studies at therapeutic doses have not shown adverse effects on male or female fertility.
How Does Marixino Interact with Other Drugs?
Quick Answer: Marixino can interact with other NMDA-active drugs (such as amantadine and ketamine), dopaminergic agents, and medicines that affect urine pH. It can be safely combined with cholinesterase inhibitors like donepezil.
Drug interactions can alter the way your medicines work or increase the risk of side effects. It is essential to inform your doctor and pharmacist about all prescription medicines, over-the-counter products, and herbal supplements you are currently taking before starting Marixino. Below is a summary of the most clinically significant interactions.
Major Interactions
The following interactions are considered clinically significant and may require dose adjustments, increased monitoring, or avoidance of the combination:
| Interacting Drug | Interaction Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Amantadine | Pharmacodynamic | Both are NMDA antagonists; increased risk of CNS adverse effects including confusion and psychosis | Avoid combination or use with close monitoring |
| Ketamine | Pharmacodynamic | Additive NMDA blockade; risk of psychotomimetic effects and CNS toxicity | Avoid combination |
| Dextromethorphan | Pharmacodynamic | Both act on NMDA receptors; possible additive CNS depression | Use with caution; inform patients about OTC cough medicines |
| Warfarin | Pharmacokinetic | Possible increase in INR | Monitor INR closely when initiating or adjusting memantine |
Minor Interactions
The following interactions are generally less clinically significant but should still be noted:
- L-dopa and dopaminergic agonists: Memantine may enhance the effects of dopaminergic drugs. Monitor for increased dopaminergic side effects such as dyskinesia or hallucinations.
- Anticholinergics: The effects of anticholinergic medications may be enhanced by memantine. Monitor for increased anticholinergic side effects (dry mouth, constipation, urinary retention).
- Barbiturates and neuroleptics: The effects of these medicines may be reduced when combined with memantine.
- Hydrochlorothiazide: Memantine may reduce the renal excretion of hydrochlorothiazide, potentially increasing its plasma levels.
- Cimetidine, ranitidine, quinidine, nicotine: These drugs share the same renal tubular transport system as memantine. Plasma levels of memantine could theoretically be elevated.
- Alkalinising agents (sodium bicarbonate, carbonic anhydrase inhibitors): These agents increase urine pH, which can reduce memantine excretion and lead to higher plasma levels.
What Is the Correct Dosage of Marixino?
Quick Answer: The recommended starting dose of Marixino is 5 mg once daily, gradually increased by 5 mg per week over 4 weeks to a maintenance dose of 20 mg daily. Dose adjustment is needed for kidney impairment.
Marixino treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. A caregiver who regularly monitors the patient should be available to oversee the patient’s medication use. Diagnosis should follow current clinical guidelines.
Adults
To reduce the risk of side effects, the dose of Marixino must be gradually increased (titrated) over the first 4 weeks of treatment. The recommended titration schedule is as follows:
| Week | Daily Dose | How to Take |
|---|---|---|
| Week 1 | 5 mg | Half a 10 mg tablet once daily |
| Week 2 | 10 mg | 5 mg twice daily (morning and evening) |
| Week 3 | 15 mg | 10 mg in the morning + 5 mg in the evening |
| Week 4 onwards | 20 mg (maintenance) | 10 mg twice daily (morning and evening) |
Marixino tablets can be taken with or without food. The tablets should be swallowed whole with a glass of water. To ensure consistent drug levels, try to take the medicine at the same times each day.
Children and Adolescents
Marixino is not recommended for use in children and adolescents under 18 years of age. There is no relevant indication for memantine in the paediatric population, and safety and efficacy have not been established in this age group. Alzheimer's disease does not occur in children.
Elderly Patients
No dose adjustment is required based on age alone. The recommended maintenance dose for elderly patients (over 65 years) is the same as for younger adults: 20 mg daily. Given that Alzheimer's disease predominantly affects the elderly, most patients in clinical trials were over 65 years of age, and the standard dosing regimen has been well-tolerated in this population.
Renal Impairment
- Mild (GFR 50–80 mL/min): No dose adjustment needed.
- Moderate (GFR 30–49 mL/min): Maximum 10 mg daily. May be cautiously titrated to 20 mg daily only if well tolerated after at least 7 days, based on individual clinical assessment.
- Severe (GFR 5–29 mL/min): Maximum dose is 10 mg daily.
Hepatic Impairment
- Mild to moderate (Child-Pugh A and B): No dose adjustment required, although data are limited.
- Severe (Child-Pugh C): Marixino is not recommended as there are no available data for this population.
Missed Dose
If you forget to take a dose of Marixino, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. If you have missed several doses, contact your doctor before resuming treatment, as re-titration may be necessary.
Overdose
In cases of overdose with memantine, symptoms may include restlessness, psychosis, visual hallucinations, drowsiness, stupor, and loss of consciousness. In clinical experience, overdoses of up to 400 mg have been reported, with relatively mild symptoms in most cases. There is no specific antidote for memantine overdose. Treatment should be symptomatic and supportive. Standard medical measures should be employed to remove the drug from the body, including gastric lavage, activated charcoal, and acidification of urine (which increases renal excretion of memantine). If you suspect an overdose, contact your local poison control centre or emergency services immediately.
What Are the Side Effects of Marixino?
Quick Answer: The most common side effects of Marixino include headache, dizziness, drowsiness, constipation, and elevated blood pressure. Most side effects are mild to moderate and tend to resolve as treatment continues.
Like all medicines, Marixino can cause side effects, although not everybody gets them. In clinical trials, the overall rate of adverse events with memantine was similar to that of placebo (inactive treatment), suggesting that the drug is generally well tolerated. The side effects are grouped below according to how frequently they occur, based on data from clinical trials and post-marketing surveillance.
Common
May affect up to 1 in 10 people
- Headache
- Drowsiness (somnolence)
- Dizziness
- Constipation
- Elevated blood pressure (hypertension)
- Shortness of breath (dyspnoea)
- Balance disorders
Uncommon
May affect up to 1 in 100 people
- Fatigue
- Vomiting
- Hallucinations (mostly in patients with severe Alzheimer's disease)
- Confusion
- Abnormal gait
- Heart failure
- Venous thrombosis / thromboembolism
- Fungal infections
Rare
May affect up to 1 in 1,000 people
- Seizures (convulsions)
- Psychotic reactions
Very Rare / Not Known
Reported after the drug was on the market
- Pancreatitis (very rare, isolated post-marketing reports)
- Hepatitis (frequency not known)
- Drug reaction with eosinophilia and systemic symptoms – DRESS (frequency not known)
- Stevens-Johnson syndrome – SJS (frequency not known)
Most common side effects are mild and tend to lessen over the course of treatment. Dizziness and drowsiness are most likely to occur during the dose titration phase (the first 4 weeks) and usually improve once the maintenance dose is reached. Hallucinations, when they occur, are more frequent in patients with severe Alzheimer's disease and should be reported to the prescribing physician.
Elevated blood pressure has been observed in some patients. If you have pre-existing hypertension, your doctor should monitor your blood pressure regularly during treatment. Constipation is a common side effect that can often be managed with adequate fluid intake, dietary fibre, and physical activity.
If you experience any side effects, including any not listed above, talk to your doctor or pharmacist. You can also report side effects directly to your national medicines regulatory authority. By reporting side effects, you can help provide more information on the safety of this medicine.
How Should You Store Marixino?
Quick Answer: Store Marixino below 30°C in its original packaging to protect from moisture. Keep out of reach of children and do not use after the expiry date.
Proper storage of medicines is essential to maintain their effectiveness and safety. Marixino film-coated tablets should be stored in accordance with the following guidelines:
- Temperature: Store below 30°C. Do not freeze. Keep the tablets away from excessive heat and direct sunlight.
- Packaging: Store in the original blister packaging or container to protect from moisture. Do not transfer tablets to a different container unless directed by your pharmacist.
- Expiry date: Do not use Marixino after the expiry date printed on the blister pack and carton. The expiry date refers to the last day of that month.
- Children: Keep this medicine out of the sight and reach of children. Store in a secure location.
- Disposal: Do not dispose of medicines via household waste or wastewater. Return unused or expired medicines to your pharmacy for safe disposal. This helps to protect the environment.
If you notice any visible damage to the tablets (such as discolouration, crumbling, or an unusual odour), do not take them. Contact your pharmacist for advice and obtain a replacement supply if needed.
What Does Marixino Contain?
Quick Answer: Each Marixino film-coated tablet contains 10 mg of memantine hydrochloride (equivalent to 8.31 mg memantine) as the active ingredient, along with several inactive excipients.
Understanding what your medicine contains is important, particularly if you have allergies or intolerances to specific ingredients. The composition of Marixino 10 mg film-coated tablets is as follows:
Active Substance
Each film-coated tablet contains 10 mg memantine hydrochloride, which corresponds to 8.31 mg of memantine (free base).
Inactive Ingredients (Excipients)
Tablet core:
- Microcrystalline cellulose
- Croscarmellose sodium
- Colloidal anhydrous silica (colloidal silicon dioxide)
- Magnesium stearate
- Lactose monohydrate
Film coating:
- Hypromellose (hydroxypropyl methylcellulose)
- Titanium dioxide (E171)
- Macrogol 400 (polyethylene glycol 400)
- Talc
- Iron oxide yellow (E172) – for 10 mg tablets
Marixino 10 mg tablets are typically pale yellow, oblong, film-coated tablets with a score line. The score line is to facilitate breaking for dose titration and is not intended to divide the tablet into equal doses unless specifically stated in your prescription.
Frequently Asked Questions About Marixino
Marixino is used to treat moderate to severe Alzheimer's disease. It contains the active substance memantine hydrochloride, which belongs to the NMDA receptor antagonist drug class. By blocking the toxic effects of excessive glutamate in the brain, it may help slow the decline in cognitive function and the ability to perform daily activities. Marixino is not a cure for Alzheimer's disease but a symptomatic treatment.
Marixino should be taken as directed by your doctor, typically once or twice daily. The dose is gradually increased over 4 weeks: starting at 5 mg daily in week 1, then 10 mg in week 2, 15 mg in week 3, and the full maintenance dose of 20 mg daily from week 4 onwards. Tablets can be taken with or without food and should be swallowed whole with water.
Yes. Clinical studies have shown no significant adverse interactions between memantine and cholinesterase inhibitors such as donepezil, galantamine, or rivastigmine. In fact, combination therapy is commonly used for moderate to severe Alzheimer's disease and is recommended by NICE guidelines. Always inform your doctor about all medicines you are taking.
The most common side effects include headache, dizziness, drowsiness, constipation, elevated blood pressure, shortness of breath, and balance disorders. These are generally mild and tend to improve as your body adjusts to the medication, particularly after the initial titration period. Contact your doctor if side effects become severe or persistent.
No. Marixino is not a cure for Alzheimer's disease. It is a symptomatic treatment that may help slow the decline in cognitive function, daily living activities, and behaviour in patients with moderate to severe Alzheimer's. The underlying disease process continues, and regular medical follow-up is essential to monitor treatment response and adjust care as needed.
All information in this article is based on international medical guidelines and peer-reviewed research: the European Medicines Agency (EMA) Summary of Product Characteristics for Marixino, NICE Technology Appraisal TA217, the FDA prescribing information for memantine (Namenda), the British National Formulary (BNF) monograph for memantine, the Cochrane systematic review by McShane et al. on memantine for dementia, and the WHO ATC classification system. All medical claims are supported by evidence level 1A.
References
This article is based on peer-reviewed international medical guidelines and evidence-based sources. All references have been verified for accuracy and relevance.
- European Medicines Agency (EMA). Marixino – Summary of Product Characteristics (SmPC). European public assessment report. Available at: www.ema.europa.eu
- McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database of Systematic Reviews. 2019;3(3):CD003154. doi:10.1002/14651858.CD003154.pub6
- National Institute for Health and Care Excellence (NICE). Technology Appraisal TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Updated 2018. Available at: www.nice.org.uk/guidance/ta217
- U.S. Food and Drug Administration (FDA). Namenda (memantine hydrochloride) – Prescribing Information. Available at: www.accessdata.fda.gov
- British National Formulary (BNF). Memantine hydrochloride monograph. Available at: bnf.nice.org.uk
- World Health Organization (WHO). ATC/DDD Index – N06DX01 Memantine. WHO Collaborating Centre for Drug Statistics Methodology. Available at: www.who.int
- Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. New England Journal of Medicine. 2003;348(14):1333–1341. doi:10.1056/NEJMoa013128
- Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA. 2004;291(3):317–324. doi:10.1001/jama.291.3.317
Editorial Team
This article was written, reviewed, and fact-checked by the iMedic Medical Editorial Team. Our editorial process ensures all medical content meets the highest standards of accuracy, evidence quality, and accessibility.